info@infactpublications.com

Harold Lloyd Kennedy

Harold Lloyd Kennedy

Harold Lloyd Kennedy

M.D., M.P.H University of Missouri, Department of Medicine and Cardiovascular Disease United States

BIOGRAPHY 20 PUBLICATIONS 100

We cordially invite you to join our board.

Your valuable suggestions improve our journal quality. We welcome you to be part of our board members.

Join Board

Education

  • 1959: B.S. - University of Denver,Denver, Colorado.
  • 1960: Washington University of St. Louis, United States.
  • 1964: M.D. - University of Missouri, School of Medicine, Missouri, United States.
  • 1977: M.P.H. - Johns Hopkins School of Hygiene and Public Health,  Baltimore, Maryland, United States.

Postgraduate Training:

  • July 1964-June 1965: Internship - Butterworth Hospital (University of Michigan), Grand Rapids, Michigan, United States.
  • July 1967-May 1969: Residency, Internal Medicine, University of Michigan Hospital, Ann Arbor, Michigan, United States.
  • June 1969-August 1970: Fellow in Cardiology, University of Michigan Hospital, Ann Arbor, Michigan, United States.
  • September 1970-February 1971: Fellow in Cardiology - St. George's Hospital (Dr. Aubrey Leatham), London, England.

Fellowship:

  • July 1970-June 1971: U.S. Public Health Service, United States.

Military Service:

  • U.S. Public Health Service (Active Duty).
  • July 1965-June 1966: Peace Corps, Brazil. 
  • July 1966-June 1967 & July 1968-June 1971 & October 1980-May 1982: Indian Health Service. 
  • July 1971-August 1973 & August 1974-October 1980: Division of Hospitals.
  • October1990-December 1990: National Health Service Corps
  • May 1994–July 2001: U.S. Air Force.

Recent Faculty Positions:

  • April 2016 to present: Adjunct Professor, Department of Medicine and Cardiovascular Disease, University of Missouri, Columbia, Missouri, United States.
  • January 2002 to January 2004: Professor, Department of Medicine, University of South Florida, Tampa, Florida, United States.
  • July 2000 to June 2001: Professor (Clinical), Department of Medicine, Division of Cardiology, University of Nevada, Reno, Nevada, United States.
  • January 2000 to 2002: Adjunct Professor, Department of Medicine, Cardiovascular Division, University of Minnesota, Minneapolis, Minnesota, United States.
  • July 1998 to December 1999: Professor, Department of Medicine, Cardiovascular Division, University of Minnesota, Minneapolis, Minnesota, United States.

Recent 100 Publications

  • Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, Arensberg D, Baker A, Friedman L, Greene HL, Huther ML, Richardson DW, and the CAST Investigators. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. N Engl J Med 1991;324:781-788.
  • Hilton TC, Kennedy HL. Effect of a community cholesterol screening program on serum total cholesterol level. Am J Cardiol 1991;68:247-249.
  • Wyse DG, Hallstrom AP, McBride R, Cohen JD, Steinberg JS, Mahmarian JJ, and the CAST Investigators. Events in the Cardiac Arrhythmia Suppression Trial (CAST): Mortality in patients surviving open label titration but not randomized to double-blind therapy. J Am Coll Cardiol 1991;18:20-28.
  • Kennedy HL and Electrophysiology/Electrocardiography Committee Members. Recommended guidelines for training in adult clinical cardiac electrophysiology. J Am Coll Cardiol 1991;18:637-640.
  • Pepine CJ, Cohn PF, Deedwania PC, Gibson RS, Gottlieb SO, Handberg E, Hill JA for the ASIST Study Group. The prognostic and economic implications of a strategy to detect and treat asymptomatic ischemia: The Atenolol Silent Ischemia Trial (ASIST) protocol. Clin Cardiol 1991;14:457-462.
  • Akiyama T, Pawitan Y, Greenberg HM and the CAST Investigators. Increased risk of death and cardiac arrest from encainide and flecainide in patients after non-Q wave acute myocardial infarction in the Cardiac Arrhythmia Suppression Trial. Am J Cardiol 1991;68:1551
  • Capone RJ, Pawitan Y, El-Sherif NE, and the CAST Investigators. Events in the Cardiac Arrhythmia Suppression Trial: Baseline predictors of mortality in placebo-treated patients. J Am Coll Cardiol 1991;18:1434-1438.
  • Epstein AE, Bigger JT, Wyse DG, and the CAST Investigators. Events in the Cardiac Arrhythmia Suppression Trial (CAST): Mortality in the entire population enrolled. J Am Coll Cardiol 1991;18:14-19.
  • Hallstrom AP, Verter J, Friedman L for the CAST Investigators. Randomizing responders. Controlled Clin Trials 1991;12:486-503.
  • Hallstrom AP, Greene HL, Huther ML and the CAST Investigators. The healthy responder phenomenon in non-randomized clinical trials. Stats in Med 1991;10:1621-1631.
  • Denes P, Gillis AM, Pawitan Y, and the CAST Investigators. Prevalence, characteristics and significance of ventricular arrhythmias detected by 24-hour continuous electrocardiographic recording in the Cardiac Arrhythmia Suppression Trial. Am J Cardiol 1991;68:887-896.
  • Greene HL, Roden DM, Katz RJ, and the CAST Investigators. The Cardiac Arrhythmia Suppression Trial: First CAST ... then CAST-II. J Am Coll Cardiol 1992;19:894-898.
  • Zientek DM, Rodriquez ER, Liebson PR, Parrillo JE, Kennedy HL, Klein LW. Validation of computerized three-dimensional reconstruction of intravascular ultrasound: Measurements of absolute luminal diameter and cross-sectional area in ex vivo human coronary arteries. J Invas Cardiol 1992;4:179-187.
  • Kennedy HL. Importance of the standard electrocardiogram in ambulatory (Holter) electrocardiography. Am Heart J 1992;123:1660-1677.
  • Shandling AH, Bernstein SB, Kennedy HL, Ellestad MH. Efficacy of three channel ambulatory electrocardiographic monitoring for the detection of myocardial ischemia. Am Heart J 1992;123:310-316.
  • Kennedy HL, Smith SC, Sprague MK, Mizera J, Buckingham TA. Limitations of ambulatory ECG real-time analysis for ventricular and supraventricular arrhythmia accuracy detected by clinical evaluation. Am J Noninvas Cardiol 1992;6:137-146.
  • The Cardiac Arrhythmia Suppression Trial-II Investigators. The effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 1992;327:227-2
  • Hallstrom AP, Bigger JT, Roden D, Friedman L, Akiyama T, Richardson DW, Rogers WJ, Waldo AL, Pratt CM, Capone RJ, Griffith L, Theroux PA, Barker AH, Woosley RL and the CAST Investigators. Prognostic significance of ventricular premature depolarizations measured 1 year after myocardial infarction in patients with early postinfarction asymptomatic ventricular arrhythmia. JACC 1992:20:259-64.
  • Wiklund I, Gorkin L, Pawitan Y and the CAST Investigators. Methods for assessing quality of life in the Cardiac Arrhythmia Suppression Trial (CAST). Qual of Life Research 1992;1:187-201.
  • Fleg JL, Kennedy HL. Long-term prognostic significance of ambulatory electrocardiographic findings in apparently healthy subjects greater than 60 years of age. Am J Cardiol 1992;70:748-751.
  • Kennedy HL, Bavishi NS, Buckingham TA. Ambulatory (Holter) electrocardiography signal-averaging: A current perspective. Am Heart J 1992;124:1339-1346.
  • Akiyama T, Pawitan Y, Campbell WB, Papa L, Barker AH, Rubbert P, Friedman L, Keller M, Josephson RA and the CAST Investigators. Effects of advancing age on the efficacy and side effects of antiarrhythmic drugs in post-myocardial infarction patients with ventricular arrhythmias. JAGS 1992; 40:66-672.
  • Buckingham TA, Lingle A, Greenwalt TD, Janosik DL, Kennedy HL, Zbilut JP. Power law analysis of the signal-averaged electrocardiogram for identification of patients with ventricular tachycardia: Effect of bundle branch block. Am Heart J 1992;124:1220-1226.
  • The Cardiac Arrhythmia Suppression Trial II Investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 1992; 327:227-233.
  • Reynolds-Haertle RA, McBride R and the CAST Investigators. Single versus double data entry in CAST. Controlled Clinical Trials 1992;13:487-494.
  • Kennedy HL. The role of ACE inhibitors in congestive heart failure. Physician Assistant J 1992;16:25-37.
  • Peters RW, Zoble RG, Liebson PR, Pawitan Y, Brooks MM, Proschan M and the CAST Investigators. Identification of a secondary peak in myocardial infarction onset 11 to 12 hours after awakening: The Cardiac Arrhythmia Suppression Trial (CAST) experience. J Am Coll Cardiol 1993;22:998-1003
  • Epstein AE, Hallstrom AP, Rogers WJ, for the CAST Investigators. Mortality following ventricular arrhythmia suppression by encainide, flecainide, and moricizine after myocardial infarction - the original design concept of the Cardiac Arrhythmia Suppression Trial (CAST). JAMA 1993;270:2451-2455.11
  • 159. Gorkin L, Schron EB, Brooks MM, and the CAST Investigators. Psychosocial predictors of mortality in the Cardiac Arrhythmia Suppression Trial. Am J Cardiol 1993;71:263-267.
  • Pitt B, Ellis SG, Mancini GBJ, Rosman HS, McGovern ME for the PLAC I Investigators. Design and recruitment in the United States of a multicenter quantitative angiographic trial of pravastatin to limit atherosclerosis in the coronary arteries (PLAC I). Am J Cardiol 1993;72:31-35.
  • Peters RW, Mitchell LB, Brooks MM, Echt DS, Barker AH, Capone R, Liebson PR, Greene HL for the CAST Investigators. Circadian pattern of arrhythmic death in patients receiving encainide, flecainide or moricizine in the Cardiac Arrhythmia Suppression Trial (CAST). J Am Coll Cardiol 1994;23:283-289.
  • Kennedy HL, Scheinman MM, Winters SL. Arrhythmias in the healthy heart. Patient Care 1994;28:145-178.
  • Wyse DG, Morganroth J, Ledingham R, Denes P, Hallstrom A, Mitchell LB, Epstein AE, Woosley RL, Capone R for the CAST and CAPS Investigators. New insights into the definition and meaning of proarrhythmia during initiation of antiarrhythmic drug therapy from the cardiac arrhythmia suppression trial and its pilot study. J Am Coll Cardiol 1994; 23:1130-40.
  • Kennedy HL, Brooks MM, Barker AH, Bergstrand R, Huther ML, Beanlands DS, Bigger JT, Goldstein S for the CAST Investigators. ßeta-blocker therapy and the Cardiac Arrhythmia Suppression Trial. Am J Cardiol 1994;74:674-680.
  • Dacanay S, Kennedy HL, Uretz E, Parrillo JE, Klein LW. Morphologic and quantitative angiographic analysis of progression of coronary stenoses: A comparison of Q wave and non-Q wave myocardial infarction. Circulation 1994; 90,4:1739-1746.
  • Kennedy HL, Goldberger AL, Graboys TB, Hancock EW. TASK FORCE 2: Training in electrocardiography, ambulatory electrocardiography and exercise testing. J Am Coll Cardiol 1995;25:1-34.
  • Goldstein S, Brooks MM, Ledingham R, Kennedy HL, Pawitan Y, Bigger JT, Epstein AE. Association between ease of suppression of ventricular arrhythmia and survival. Circulation 1995;91:79-83.
  • Hallstrom A, Pratt CM, Greene HL, Huther M, Gottlieb S, DeMaria A, Young JB for the CAST Investigators. Relations between heart failure, ejection fraction, arrhythmia suppression and mortality: Analysis of the Cardiac Arrhythmia Suppression Trial. J Am Coll Cardiol 1995;25:1250-1257.
  • Hallstrom AP, Anderson JL, Carlson M, Davies R, Greene HL, Kammerling JM, Romhilt DW, Duff HJ, Huther M for the CAST Investigators. Time to arrhythmic, ischemic, and heart failure events: exploratory analyses to elucidate mechanisms of adverse drug effects in the Cardiac Arrhythmia Suppression Trial. Am Heart Journal 1995;130:71-79.
  • Kennedy HL, Rosenson RA. Physician use of beta-adrenergic blocking therapy - A changing perspective. J Am Coll Cardiol 1995;26:547-552.
  • Pitt B, Mancini GBJ, Ellis SG, Rosman HS, Park JS, McGovern ME, and the PLAC I Investigators. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): Reduction in atherosclerosis progression and clinical events. J Am Coll Cardiol 1995;26:1133-9.
  • Peters RW, Brooks MM, Todd L, Liebson PR, Wilhelmsen L for the CAST Investigators. Smoking cessation and arrhythmic death: The CAST experience. J Am Coll Cardiol 1995;26:1287-92.
  • Josephson RA, Chahine RA, Morganroth J, Anderson J, Waldo A, Hallstrom A for the CAST Investigators. Prediction of cardiac death in patients with a very low ejection fraction after myocardial infarction: A Cardiac Arrhythmia Suppression Trial (CAST) study. Am Heart Journal 1995;130:685-691.
  • Hochman JS, Brooks MM, Morris M, Ahmad T, and the CAST Investigators. Prognostic significance of left ventricular aneurysm in the Cardiac Arrhythmia Suppression Trial (CAST). Am Heart J 1994;127:824-36.
  • Cooper DH, Kennedy HL, Lyyski DS, Sprague MK. Holter "Triage" Ambulatory ECG Analysis: Accuracy and Time Efficency. J of Electrocardiology 1996;29:33-38.
  • Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Heart Rate Variability. Standards of measurement, physiological interpretation, and clinical use. Circulation 1996;93:1043-1065.
  • Peters RW, Brooks MM, Zoble RG, Liebson PR, Seals AA, for the CAST Investigators. Chronobiology of acute myocardial infarction: Cardiac Arrhythmia Suppression Trial (CAST) Experience. Am J Cardiol 1996;78:1198-1201.
  • Kennedy HL. Beta-blockers in congestive heart failure: the rooster and the elder. Br J Cardiol 1996;3:222-240.
  • Kennedy HL. The beta-blocker bandwagon: electrophysiologists are now hopping on! Br J Cardiol 1997;4:122-124.
  • Mason JW, Hancock EW, Saunders DE, Schuger CD, Griffin JC, Kennedy HL, Buxton AE, Mittal N. American College of Cardiology Report on ECGEXAM. J Am Coll Cardiol 1997;29:466-468.
  • Kennedy HL. Beta-blocker prevention of proarrhythmia and proischemia. Clues from CAST, CAMIAT and EMIAT. Am J Cardiol 1997;80:1208-1211.
  • Kennedy HL. Beta-blockade, ventricular arrhythmias and sudden cardiac death. Am J Cardiol 1997;80:29J-34J.
  • Kennedy HL. Heart rate variability - A potential non-invasive prognostic index in the critically ill patient. Crit Care Med 1998;26:213-214.
  • Kennedy HL. The importance of randomized clinical trials and evidence-based medicine. A Clinician’s Perspective. Clin Cardiol 1999;22:6-12.
  • Fesmire SI, Marcoux LG, Lyyski DS, Sprague MK, Kennedy HL, Eichhorn EJ. Effect of selective versus nonselective beta blockade on QT dispersion in patients with nonischemic dilated cardiomyopathy. Am J Cardiol 1999;84:24-28.
  • MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet 1999; 353:2001-07.
  • Goldstein S, Kennedy HL, Hall C, Anderson JL, Gheorghiade M, Gottlieb S, Jessup M, Karlsberg RP, Friday G, Haskell L. Metoprolol CR/XL in patients with heart failure: A pilot study examining the tolerability, safety, and effect on left ventricular ejection fraction. Am Heart J 1999;138:1158-65.
  • ATLAS Study Group. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation 1999;100:2312-18.
  • MERIT-HF Study Group. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). JAMA 2000;283:1295-302.
  • Ryden L, Armstrong PW, Cleland JGF, ATLAS Study Group. Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Eur Heart J 2000; 21:1967-78.
  • Kennedy HL. Current utilization trends for beta-blockers in cardiovascular disease. Am J Med 2001;110 Suppl 5A:2S-6S.
  • The Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001;344:1659-67.
  • Adabag S, Kennedy HL. Discharge prescription following acute myocardial infarction. J Crit Illness 2001;16:307-17.
  • Goldstein S, Fagerberg B, Hjalmarson A, MERIT-HF Study Group. Metoprolol controlled release/extended release in patients with severe heart failure. Analysis of the experience in the MERIT-HF Study. J Am Coll Cardiol 2001; 38:932-8.
  • Kadish AH, Buxton AF, Kennedy HL, Knight BP, Mason JW, Shuger CD, Tracy CM. ACC/AHA clinical competence statement on electrocardiography: a report of the American College of Cardiology/American Heart Association/Amercian College of Physicians-American Society of Internal Medicine Task Force on Clinical Competence (ACC/AHA Committee to Develop a Clinical Competence Statement on Electrocardiography and Ambulatory Electrocardiography). J Am Coll Cardiol 2001;38:2091-100.
  • Moss AJ, Zareba W, Benhorin J, Couderc JP, Kennedy H, Locati-Heilbron E, Maison-Blanche P. ISHNE guidelines electrocardiographic evaluation of drug-related QT prolongation and other alterations in ventricular repolarization: task force summary Ann of Nonivas Electrocardiology 2001;6:333-41.
  • Gottlieb SS, Fisher ML, Kjekshus J, MERIT-HF Investigators. Tolerability of B-blocker initiation and titration in the Metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). Circulation 2002;105:1182-88.
  • Kennedy HL, Rosenson RS. Physicians’ perspective of “Class Effects”: a need for thoughtful re-evaluation. J Am Coll Cardiol 2002;40:19-26.
  • Ghali JK, Pina IL, Gottlieb SS, Deedwania PC, Wikstrand JC, MERIT-HF Study Group. Metoprolol CR/XL in female patients with heart failure. Circulation 2002:105:1585-91.
  • Wikstrand J, Hjalmarson A, Waagstein F, Fagerberg B, Goldstein S, Kjekshus J, Wedel H, MERIT-HF Study Group. Dose of Metoprolol CR/XL and clinical outcomes in patients with heart failure. J Am Coll Cardiol 2002;40:492-8.
  • Herlitz J, Wikstrand J, Denny M, MERIT-HF Study Group. Effects of metoprolol CR/XL on mortality and hospitalizations in patients with heart failure and history of hypertension. J Card Fail 2002;8(1):8-14.
  • Kennedy HL. Ventricular ectopy in athletes. Don’t worry…………more good news! J Am Coll Cardiol 2002;40:453-6.
  • Pfeffer MA, Swedberg K, Granger CB, the CHARM Investigators. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003;362:759-66.
  • McMurray JJV, Ostergren J, Swedberg K, the CHARM Investigators. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362:767-71.
  • Goldstein S, Deedwania P, Gottlieb S, MERIT-HF Study Group. Metoprolol CR/XL in black patients with heart failure. Am J Cardiol 2003;92:478-80.
  • Granger CB, McMurray JJV, Yusuf S, the CHARM Investigators. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003;362:772-6.
  • Yusuf S, Pfeffer MA, Swedberg K, the CHARM Investigators. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003;362:777-81.
  • Deedwania PC, Gottlieb S, Ghali JK, MERIT-HF Study Group. Efficacy,safety and tolerability of -adrenergic blockade with Metoprolol CR/XL in elderly patients with heart failure. Europ Heart J 2004;25:1300-09.
  • Young JB, Dunlap ME, Pfeffer MA, and CHARM Investigators. Mortality and morbidity reduction with candesartan in patients with chronic heart failure and left ventricular systolic dysfunction. Circulation 2004;110:2618-26.
  • Granger BB, Swedberg K, Ekman I, and CHARM Investigators. Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomized controlled clinical trial.
  • Solomon SD, Anavekar N, Skali H, and CHARM Investigators. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation 2005;112:3738-44
  • Kennedy HL. The history,science and innovation of Holter technology. Ann Noninvas Electrocardiol 2006;11:85-94.
  • Hillege HL, Nitsch D, Pfeffer MA, and CHARM Investigators. Renal function s a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 2006;113:671-8.
  • Kennedy HL. Cryptogenic stroke and migraine headache: The clinical cardiologist’s viewpoint. Hospital Chronicle 2006.
  • Pocock SJ, Wang D, Pfeffer MA, and CHARM Investigators. Predictors of mortality and morbidity in patients with chronic heart failure. Europ Heart J 2006;27:65-75.
  • Ducharme A, Swedberg K, Pfeffer MA, and CHARMInvestigators. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesart in Heart Failure: Assesment of reduction in mortality and morbidity (CHARM) program. Am Heart J. 2006;152:86-92.
  • O’Meara E, Clayton T, McEntegart MB,and CHARMInvestigators. Clinical correlates and consequences of anemia in a broad Spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assesment of reduction in Mortality and Morbidity (CHARM) program. Circulation 2006;113:986-94.
  • Kern MJ, Vandormael M, Deligonul U, Labovitz A, Harper M, Gibson P, Presant S, Kennedy HL. Intracoronary nitroglycerin and regional coronary blood flow responses. during coronary angioplasty in patients. J of Intervent Cardiol 2007;1:49-57.
  • Kern MJ, Presant S, Deligonul U, Vandormael M, Kennedy HL. The effects of coronary angioplasty on nitroglycerin- induced augmentation of regional myocardial blood flow. J of Intervent Cardiol 2007;1:121-130.
  • 220.O’Meara E, Clayton T, McEntegart MC, and CHARM Investigators Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure. Circulation 2007;115:3111-20.
  • Felker GM, Allen LA, Pocock SJ, and CHARM Investigators. Red cell distribution width as a novel prognostic marker in Heart failure. J Am Coll Cardiol 2007;50:40-7.
  • Solomon SD, Dobson J, Pocock S, and CHARM Investigators. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation 2007;116:1482-1487.
  • Desai AS, Swedberg K, McMurray JJV, and CHARM Investigators Incidence and predictors of hyperkalemia in patients with heart failure. J Am Coll Cardiol 2007;50:1959-66.
  • Kenchaiah S, Pocock SJ, Wang D, and CHARM Investigators. Body mass index and prognosis in patients with chronic heart failure. Circulation 2007;116:627-36.
  • Abrahamsson P, Dobson J, Granger CB, and CHARMInvestigators Impact of hospitalization for acute coronary events on subsequent mortality in patients with chronic heart failure. Europ Heart J 2009;30:338-45.
  • Kennedy HL. The evolution of ambulatory ECG monitoring. Prog Cardiovasc Dis 2013;56:127-32.
  • Hombach V, Kennedy HL, Moss AJ, Bayes de Luna A, Zareba W. Shlomo Stern (1928-2013)- visionary leader with great legacy in memoriam. Ann of Noninvas Electrocard 2013;18:494-8.
  • Kennedy HL. Silent Atrial Fibrillation: Definitions, Clarification, and unanswered issues. Ann of Noninvas Electrocard 2015;20:518-525.
  • Dilaveris PE, Kennedy HL: Silent atrial fibrillation: Epidemiology, diagnosis, and clinical impact. Clin Cardiol 2017;40:413-418.
  • Kennedy HL. Beta-blocker Therapy in Acute Coronary Syndromes: a Time-Trend Interpretation of Evolving Clinical Benefits. Cardiovasc Drugs Ther. 2018 Sep 20. doi: 10.1007/s10557-018-6829-3.

Are you interested in submitting your research paper?

Thank you for choosing us. We recommend you to go through our guidelines before submitting the paper.

Submit Manuscript
Logo

Infact Publications is the state-of-the-art platform to showcase medical journals across scientific community and a one-stop solution for publishing the manuscripts of varied medical specialities.

Main Links

Useful Links

Our Contacts

INFACT PUBLICATIONS LLC,
16192 Coastal Highway,
Lewes, Delaware 19958
USA

info@infactpublications.com
https://infactpublications.com